Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 3No longer available 1Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 3Observational 1Expanded_access 1

Sponsor

Cancer Type

Thoracic 5

Conditions

Carcinoma, Non-Small-Cell Lung 5Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Non-small Lung Cancer 1Neoplasms by Site 1Neoplasms 1Lung Neoplasms 1Lung Diseases 1Carcinoma, Bronchogenic 1Carcinoma 1Breast Neoplasms 1

Interventions

Carboplatin 784Pemetrexed 607Cisplatin 545Paclitaxel 491pembrolizumab 464Docetaxel 440Gemcitabine 328Erlotinib Hydrochloride 307Radiotherapy 258Nivolumab 244Bevacizumab 233osimertinib 178Drug Therapy 164durvalumab 157atezolizumab 135Gefitinib 134Radiosurgery 133Vinorelbine 111Cetuximab 97130-nm albumin-bound paclitaxel 94Ipilimumab 86Magnetic Resonance Spectroscopy 84Taxes 79Surgical Procedures, Operative 74Afatinib 68Albumin-Bound Paclitaxel 66Specimen Handling 61Etoposide 61Cyclophosphamide 60tislelizumab 59

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × taletrectinib × Clear all
NCT07154706 2026-05-19

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

Nuvation Bio Inc.

Phase 3 Recruiting
180 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06564324 2026-04-13

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

Nuvation Bio Inc.

Phase 3 Recruiting
194 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04919811 2026-01-07

TRUST-II

Nuvation Bio Inc.

Phase 2 Active not recruiting
217 enrolled 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06841874 2025-12-24

Tale EAP

Nuvation Bio Inc.

No longer available
Thoracic

Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT07008287 2025-07-22

Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases

Innovent Biologics (Suzhou) Co. Ltd.

Recruiting
100 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡